Denosumab approved in US for male osteoporosis
This article was originally published in Scrip
The US FDA has approved Amgen's Prolia (denosumab) for the additional indication of male osteoporosis, providing a new alternative to older drugs such as bisphosphonates in a condition affecting increasing numbers of men.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.